Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 233

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 233
---
) |

| - | GlyTherix, Minomic & Litmus, and Coya (a pharmaceutical company) |

| - | FreeWire (an ultra-fast charging technology company) |

| - | Seismic (a wearable technology company) |

| - | NuraLogix (a facial recognition for blood pressure monitoring company, showcased at CES 2023) |

During this period,

| ○ | FutureTech                                                                                                
 entered into non-disclosure agreements with these Potential Targets;                                      |
| ○ | Received management presentations or confidential information memorandums from more than twenty Potential 
 Targets;                                                                                                  |

| ○ | Fielded                                                         
 two to four meetings with at least seven Potential Targets; and |

| ○ | Obtained access to a virtual dataroom, and conducted due diligence of varying degrees, with respect to 
 eleven Potential Targets.                                                                              |

Following such reviews,
and at various points in time, these discussions with Potential Targets (except Hanson Robotics) were discontinued for various
reasons, including the maturity of the business, the lack of a near-term path to profitability, the valuation of the Potential Target,
the strength of the management team of the Potential Target, and the lack of competitive advantages or sufficient barriers to entries
for the Potential Target.

On October 31,
2022, Mr. Bradford A. Zakes informed Wicab China’s general manager, Mr. Kenny Min Zhou, by phone of the decision to exclude Wicab
China from the C&E Agreements.

On January 18,
2023, Longevity and Wicab China signed a Mutual Consent to Termination to terminate the Contribution and Exchange Agreement amongst the
parties.

From February 2023 to July
2023, FutureTech focused its efforts on Hanson Robotics, and engaged in extensive discussions and due diligence, and conducted
various evaluations. However, FutureTech’s due diligence identified significant issues, such as:

| - | Hanson Robotics' financial condition did not meet the required standards for a successful business combination. |

| - | The company was facing substantial financial pressure, including liquidity challenges and unresolved 
 financial liabilities.                                                                               |

| - | These                                                                                         
 issues were deemed unlikely to be resolved in the near term, making the company an unsuitable 
 candidate for a business combination at that time.                                            |

As a result, FutureTech decided
to discontinue its discussions with Hanson Robotics and refocus its efforts on identifying alternative targets.

From August 2023 to May 2024,
FutureTech resumed